TABLE 2.
In vivo antimalarial activity of cyclen 4-aminoquinoline analog compound 4
| Compound or drug | Dose (days × amt [mg/kg]) | % Suppression of parasitemiaa
|
MSTb (no. of survivors/total) | No. cured/total (%)c | ||
|---|---|---|---|---|---|---|
| Day 5 | Day 7 | Day 10 | ||||
| Vehicled | 22.2 (0/5) | 0/5 | ||||
| Compound 4 | 3 × 1.1 | 65.2 | 33.3 | 22.7 | 23.8 (0/5) | 0/5 |
| 3 × 3.3 | 84.6 | 44.1 | 43.9 | 22.8 (0/5) | 0/5 | |
| 3 × 10 | 96.3 | 59.7 | 40.9 | 26.2 (2/5) | 0/5 | |
| 3 × 30 | 100 | 100 | 100 | >28 (5/5) | 3/5 (60) | |
| Chloroquine | 3 × 30 | 100 | 100 | 100 | >28 (4/4) | 3/4 (75) |
a
Percent suppression of parasitemia compared to the vehicle control.
b
MST, mean survival time in days(number of mice that survived until 28th day postinfection/total number of mice in group).
c
Mice with no parasitemia until day 28 postinfection/total mice in group(% cured).
d
The vehicle was 0.1 N HCl.